血液透析患者接受高剂量促红细胞生成素后死亡率增加:倾向性评分匹配分析
多中心观察性回顾性倾向性评分匹配研究分析了1679例新发血液透析患者的每周ESA剂量与死亡和住院的关系。结果显示高剂量ESA(>8127.4 IU/周)与全因死亡风险增加相关,倾向性评分匹配证实每周ESA剂量>8000 IU是全因死亡和住院的独立预测因素。
要点
- 高剂量ESA(>8127.4 IU/周)与血液透析患者全因死亡风险增加相关
- 倾向性评分匹配后,每周ESA剂量>8000 IU仍为全因死亡和住院的独立预测因素
- 高ESA剂量也是心血管死亡及全因、心血管和感染相关住院的独立预测因素
核心结论
- 每周ESA剂量>8000 IU与血液透析患者全因死亡和住院风险增加相关。
研究设计与样本
- 多中心、观察性、回顾性倾向性评分匹配研究,纳入1679例新发血液透析患者。
主要发现
- Kaplan-Meier生存曲线显示高剂量ESA(>8127.4 IU/周)患者死亡风险显著增加。
- 多变量Cox模型确定高ESA剂量为全因和心血管死亡的独立预测因素。
- logistic回归模型确定高ESA剂量为全因、心血管和感染相关住院的独立预测因素。
- 倾向性评分匹配分析(两组各324例,每周ESA剂量>8000 IU vs ≤8000 IU)确认>8000 IU为全因死亡和住院的独立预测因素。
关键数值与推荐
- 每周ESA剂量阈值:>8000 IU。
- 高剂量组定义:>8127.4 IU/周(五分位分组)。
临床怎么用
- 在血液透析患者中,应关注每周ESA剂量,高剂量(>8000 IU/周)可能增加死亡和住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are widely used to treat anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in multiple studies, with correlates derived for elevated cancer incidence and mortality. Whether these associations are related to ESA dose or the typology of the patient remains obscure. METHODS: A multicentre, observational retrospective propensity score-matched study was designed to analyse the effects of weekly ESA dose in 1679 incident haemodialysis (HD) patients. ESA administration was according to standard medical practice. Patients were grouped as quintiles, according to ESA dose, in order to compare mortality and hospitalization data. Using propensity score matching (PSM), we defined two groups of 324 patients receiving weekly threshold ESA doses of either > or ≤8000 IU. RESULTS: Kaplan-Meier survival curves indicated significant increases in the risk of mortality in patients administered with high doses of ESAs (>8127.4 IU/week). Multivariate Cox models identified a high ESA dose as an independent predictor for all-cause and cardiovascular (CV) mortality. Moreover, logistic regression models identified high ESA doses as an independent predictor for all-cause, CV and infectious hospitalization. PSM analyses confirmed that weekly ESA doses of >8000 IU constitute an independent predictor of all-cause mortality and hospitalization, even though the adjusted cohort displayed the same demographic features, inflammatory profile, clinical HD parameters and haemoglobin levels. CONCLUSIONS: Our data suggest that ESA doses of >8000 IU/week are associated with an increased risk of all-cause mortality and hospitalization in HD patients.
引用
- Pérez-García R, Varas J, Cives A, et al. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant. 2018. PMID: 29036505. doi:10.1093/ndt/gfx269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。